NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without ...
Bladder control issues affect millions of people worldwide, impacting daily activities and quality of life. While common, these conditions remain treatable through various medical interventions, ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
SurvivorNet on MSN
Muscle invasive bladder cancer: Understanding your treatment options
Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder ...
SurvivorNet on MSN
A breakthrough for muscle-invasive bladder cancer: Padcev plus Keytruda drug combo could transform treatment around surgery
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS with or without papillary tumors. FDA interactions centered on updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results